Quantcast

Latest advanced breast cancer Stories

2008-11-03 18:00:20

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. announced today that its drug candidate for metastatic breast cancer, BZL101, will advance to Phase 2 clinical testing after the successful completion of a second Phase 1 clinical trial. The Phase 1B clinical trial was conducted to identify the maximum tolerated dose of BZL101 and to determine the safety and feasibility of the company's novel, oral, anticancer treatment. A total of 27 women with metastatic breast cancer...

2008-10-21 09:00:12

TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, today announced that updated preliminary data from the first stage of its Phase II trial evaluating bavituximab in combination with docetaxel showed that 10 of 14 (71%) evaluable breast cancer patients achieved an objective tumor response according to RECIST criteria. The company also reported...

2008-10-08 09:00:50

Peregrine Pharmaceuticals, a clinical stage biopharmaceutical company, has completed enrollment in the first stage of a Phase II trial of bavituximab in combination with chemotherapy in patients with advanced breast cancer. This is Peregrine's second Phase II study for the treatment of breast cancer. The main objective of the multi-center, open-label, safety and efficacy study is to assess patients' overall response rate to a regimen combining bavituximab with the chemotherapy drugs...

2008-10-07 09:00:15

TUSTIN, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has completed enrollment in the first stage of a Phase II trial of bavituximab in combination with chemotherapy in patients with advanced breast cancer. This is Peregrine's second Phase II study for the treatment of breast cancer. The main...

2008-10-01 09:00:49

Today, those living with advanced breast cancer now have an online resource available specifically for them. AdvancedBreastCancerCommunity.org is the first comprehensive online resource to serve as a clearinghouse of information for those impacted by advanced breast cancer. The new web portal represents the collective thinking, expertise and resources from 13 leading cancer patient advocacy groups and also offers patients, caregivers, families and friends with a place to connect online....

2008-09-30 09:00:18

Cancer drug developer Antisoma has started a Phase II trial evaluating the addition of AS1402 to the endocrine therapy letrozole in post-menopausal women receiving first-line treatment for advanced breast cancer. Approximately 110 patients will be randomly assigned to receive either letrozole plus AS1402 or standard treatment with letrozole alone. The safety of the AS1402-letrozole combination will be evaluated and its efficacy compared with that of letrozole alone. Measures of efficacy...

2008-08-11 09:00:21

TUSTIN, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The new trial is the second Phase II study evaluating bavituximab in advanced breast cancer patients, and Peregrine also is conducting a third Phase II combination therapy trial of bavituximab in...

2008-07-14 09:01:11

TUSTIN, Calif., July 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , today announced financial results for fiscal year (FY) 2008 ended April 30, 2008. Total revenues for FY 2008 increased 64% to $6,093,000, primarily reflecting increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary. Total costs and expenses in FY 2008 increased to $30,233,000 from $25,618,000 in FY 2007. Increased costs of contract manufacturing directly related...

2008-04-18 12:00:19

NUTLEY, N.J., April 18 /PRNewswire/ -- A novel biweekly dosing schedule of Xeloda(R) (capecitabine) enabled safe delivery of higher daily doses in the treatment of advanced breast cancer, according to an investigational study published in the April 10, 2008 issue of the Journal of Clinical Oncology. The data showed that a seven-days-on/seven-days-off (7-on/7-off) regimen, called "dose dense," was generally well-tolerated up to 2,000 mg twice daily (4,000 mg/day), providing a potential...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.